@Article{Samotij2015,
journal="Dermatology Review/Przegląd Dermatologiczny",
issn="0033-2526",
volume="102",
number="3",
year="2015",
title="Special papersDiagnostic and therapeutic advances in dermatomyositis",
abstract="Dermatomyositis (DM) is one of the so-called idiopathic inflammatory myopathies (IIM). Dermatomyositis is an autoimmune disorder characterized by the presence of cutaneous lesions and/or symptoms of muscle involvement with the following variants: the “classic” variant of DM, juvenile DM, paraneoplastic DM, drug-induced DM and amyopathic DM. Dynamic discoveries of novel autoantibodies, including anti-TIF1, anti-NXP2, anti-SAE or anti-MDA5, related to certain DM variants, have been described in recent years. It seems that these antibodies will contribute to better recognition of DM and its particular variants, a better risk stratification for predicting internal organ involvement, and to a global improvement of treatment outcome. Corticosteroids remain the mainstay of DM therapy, but new immunomodulatory and immunosuppressive agents, including biologicals, resulted in a significant increase of the survival rate of DM patients. Here, we review the current literature data on DM with special emphasis on new trends in its diagnostics and treatment.",
author="Samotij, Dominik
and Szczęch, Justyna
and Reich, Adam",
pages="183--197",
doi="10.5114/dr.2015.51919",
url="http://dx.doi.org/10.5114/dr.2015.51919"
}